Cipla Ltd vs Ind Swift Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 15, 2026

Key Highlights

The Latest Trading Price of Cipla Ltd is ₹ 1438 as of 14 May 15:30 . The P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 22.1 on March 2025 . This represents a CAGR of -4.14% over 5 yearsThe P/E Ratio of Ind-Swift Ltd changed from 1.5 on March 2023 to 0 on March 2025 . This represents a CAGR of -100.00% over 3 years The Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 116434 crore on March 2025 . This represents a CAGR of 12.11% over 5 yearsThe Market Cap of Ind-Swift Ltd changed from ₹ 60.61 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 4 years The revenue of Cipla Ltd for the Mar '26 is ₹ 6689 crore as compare to the Dec '25 revenue of ₹ 7280 crore. This represent the decline of -8.12% The revenue of Ind-Swift Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Cipla Ltd for the Mar '26 is ₹ 1103 crore as compare to the Dec '25 ebitda of ₹ 1185 crore. This represent the decline of -6.95% The ebitda of Ind-Swift Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 550.11 crore over 8 quarters. This represents a CAGR of -31.61% The net profit of Ind-Swift Ltd changed from ₹ 28.24 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 25.05 % on March 2025 . This represents a CAGR of 8.92% over 5 yearsThe Dividend Payout of Ind-Swift Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Cipla Ltd

Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Ind-Swift Ltd

Ind-Swift Limited (ISL) is an India-based pharmaceutical company.
The Company is engaged in the manufacturing and marketing of pharmaceutical finished dosage.
The products manufactured by the company include cephalosporins, quinolones, aminoglycosides, macrolides, chloramphenicol, tetracyclines, sulphonamides, antianaerobics and anti-fungals. The company manufactures various dosage forms, including oral solutions and suspensions; dry syrups and hard gelatin capsules; tablets; dermatologicals comprising creams, ointments, and gels; eye and ear drops; and injectables.
The company, through their different divisions, markets formulations focusing on the needs of various therapeutic segments, such as diabetology, cardiovascular, anesthesiology, oncology, ophthalmology, neuropsychiatry, gynecology, pediatric, ENT, surgery, internal medicine, dermatology, urology, cardiology, and dental specialty.

FAQs for the comparison of Cipla Ltd and null

Which company has a larger market capitalization, Cipla Ltd or Ind-Swift Ltd?

Market cap of Cipla Ltd is 116,211 Cr while Market cap of Ind-Swift Ltd is 85 Cr

What are the key factors driving the stock performance of Cipla Ltd and Ind-Swift Ltd?

The stock performance of Cipla Ltd and Ind-Swift Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Ind-Swift Ltd?

As of May 15, 2026, the Cipla Ltd stock price is INR ₹1438.65. On the other hand, Ind-Swift Ltd stock price is INR ₹15.7.

How do dividend payouts of Cipla Ltd and Ind-Swift Ltd compare?

To compare the dividend payouts of Cipla Ltd and Ind-Swift Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.